Member Info for Doorstop123

Fingers crossed for a nice Xmas present for all I3e holders.

Think we may all deserve it this year!

“The supply of these new test kits is currently limited in the face of very high global demand and consequently it was necessary to contract for supply on an ex-works basis for product manufactured in China in order to secure the required quantity of product and prevent gazumping. Where product has be sourced on an ex works basis it is imperative that this product is moved at the earliest opportunity to prevent it being sold to higher bidders. In addition the rising rates of infection in the UK and predicted growth in cases over the coming months, has created an urgent need for these new test kits to support the testing programme in the UK”

If only there was a stable sovereign supply to overcome all of these issues...

“Is it me but there seems to be much less talk about testing (worrying). As more and more people are vaccinated there becomes less need for testing”

Really can’t see venues for crowds or groups of people opening any time soon without testing.

Care home visitors

Hospital visitors

NHS staff

Teachers

Pupils

Airline passengers

Train passengers

List goes on and on multiplied by every country around the globe.

Let’s not forget UK is fore runner with vaccine yet vast majority of global population is living in a country where mass vaccination is much further down the road.

And we have no idea how long vaccine immunity lasts - will current people being vaccinated still be immune by September 2021?

“If AVCT gets a LFT to market by Spring/Summer (Exactly 12 months behind Alastairs original timeline)”

What a ridiculous comment! In June results presentation AS states hoping for clinical validation to begin in q4.

Management have always had things in control.

It seems the final sentence of the Nov 23rd rns confirms there will be multiple tests with each having its own use.

Assume a general population test will be less sensitive than a test required to enter a care home for example.

Or a test to board a plane or work front line NHS may be more sensitive than a test to enter a small concert or gathering.

Tbh my concerns are very similar to this.

Especially considering we each carry the virus in a different way, will swab a different way, will swab at different times etc etc

Surely a viral load that is infectious is one person may not be in another and vice versa?

How can avct produce a test that will cover each aspect and still give an accurate yes no answer to infectiousness?

Probably impossible to do so, but perhaps will just process as much data as poss and get as accurate as is possible a test out there, or have multiple tests for different applications and category of person being tested (teachers, pupils, healthcare, care home, concert goers etc).

May explain some of the delays

Good point about comparing the styles of Today’s rns with recent lft ones. Like you say hints further at some sort of restriction on lft communications - be it an NDA or commercial sensitivities.

Hopefully, all revealed very soon in the New Year!

Small tick up on TSX last evening - trading at 5.8p equivalent.

Very tempting to top up sub 5p

Just as happy to see the sp do well this morning but a nice dip could well be the best top up opportunity we get before Xmas.

Any biggish dip will be heavily bought in anticipation of major announcements in the New Year...

Finger on the button ready and waiting for £1

“A new legally verified summary presentation will be available in early January as part of the planned Open Offer to Shareholders”

Update on egr website for any who may be interested

Considering how share price sensitive the information is, then I would be very surprised if there were not some form of NDA.

Plus, considering how crucial these lfts could be to re-opening economies, for sure governments will want procurement to be confidential. Bit of an arms race going on possibly!

Perhaps the last chance to buy below the placing price.

Cheaper than the price level that one of the Globe’s most renowned investors saw as great value...

The commercial opportunity created by the SARS-CoV-2 spike Affimer binders is substantial. The performance of the Affimer reagents has been demonstrated clearly by Avacta in an ELISA laboratory test, and the remaining technical risk is related to successfully completing clinical validation with a product that can be manufactured at scale. The Group is working hard to put in place multiple manufacturing partnerships so that it can fully capitalise on the launch of a rapid coronavirus antigen test. Multiple other commercial opportunities have been created by the SARS-CoV-2 spike binding Affimer reagents, such as the collaboration with Adeptrix to develop a mass spectrometer based laboratory test, but also including a number of currently undisclosed potential licensing opportunities for COVID-19 testing. The value of all these developments is impossible to quantify at this stage, but it is clear that global demand for COVID-19 rapid testing solutions is potentially worth billions of pounds.

Alastair in September -

“It is essential that a robust process is developed that can produce the antigen test at scale for clinical validation in Q4, and good progress is being made in this regard. Once a robust process has been established it should be straightforward to transfer that to a number of manufacturers globally to meet the anticipated demand”

Deadline hit :)

“The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test.”

End of November, just about to enter phase 2 before moving on to phase 3.

Did the last rns say we were going to trial across Europe!?

After 2 years of talks with AS, Buffet’s successor makes unprecedented £10m investment in to an Aim listed biotech company at 120p.

Investors siding with Alexander, Buffet and Ruane this morning.

Everything is moving along just fine!

Step by step towards the worlds best performing Covid tests

Why would this famous investor invest in aim-listed avct? Perhaps in preparation for a multi billion dollar Nasdaq listing?

“Twelve years ago, Greg Alexander joined us out of Yale where, despite his economics degree, it appears that he spent most of his time reading annual reports. He is highly creative and still spends at least eight hours a day consuming annual reports. I don’t know anyone who processes more ideas with greater analytical depth and he is excellent at cutting through to the heart of an issue. He is a master of chewing through immense detail to reach original insights and judgments about our portfolio companies.”)